Exec Chat: Miach Orthopaedics Bullish On BEAR For Repairing, Not Replacing, Torn ACLs

 
• By Marion Webb

Medtech Insight spoke with Martha Shadan, CEO of Miach Orthopaedics, about the company’s marketing efforts for its US FDA-cleared BEAR implant for treating anterior cruciate ligament (ACL) tears, ongoing clinical trials, plans for the rest of the year, and highlights from the AAOS 2022 event.

Kneeinjury
• Source: Alamy

Miach Orthopaedics’ CEO Martha Shadan expressed excitement about surgeons’ uptake of its now commercially available bio-engineered Bridge-Enhanced ACL Restoration, BEAR implant, designed to get patients with anterior cruciate ligament tears back on their feet and back to their sports faster post-surgery compared with standard ACL reconstruction.

Since Miach launched the BEAR implant this January, after receiving US Food and Drug Administration de novo clearance in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Orthopedics

More from Device Area